Participants in the open-label levetiracetam study had previously failed on between one and three preventive drugs and had taken no more than one antiepileptic agent
In addition to Lennox-Gastaut syndrome (LGS) treatment Inovelon(R)/Banzel(R), Eisai currently markets Zonegran(R) (sodium/calcium channel blocking antiepileptic agent
marketed in Europe, the United States and Asia under license from the originator, Dainippon Sumitomo Pharma Co.
announced today that it has received manufacturing and marketing authorization in Japan from the Japanese Ministry of Health, Labour and Welfare (MHLW) for antiepileptic agent
Inovelon(R) (rufinamide), approving the drug as an adjunctive therapy to other antiepileptic drugs (AEDs) in the treatment of Lennox-Gastaut syndrome (LGS), a rare disorder.
New research presented at CHEST 2008, the 74th annual international scientific assembly of the American College of Chest Physicians (ACCP), shows that the use of propofol as an antiepileptic agent
in patients with refractory status epilepticus (RSE), prolonged seizures that do not respond to initial treatment, was associated with significant mortality and morbidity.
The antiepileptic agent
was employed as add-on therapy in 32 patients with refractory tics and as monotherapy in 7.
EML) situated within the company's European Knowledge Centre (EKC), has received a license (marketing authorization type II variation: addition of manufacturing site) from the European regulatory authorities for solid dose manufacturing of the antiepileptic agent
Fycompa(R) (perampanel), a first-in-class AMPA receptor antagonist discovered and developed in-house, at its Hatfield production plant.
May 20 /PRNewswire/ -- Eisai Corporation of North America announced today the publication of a placebo-controlled study in Neurology that found patients with Lennox-Gastaut syndrome (LGS) treated with the investigational antiepileptic agent
rufinamide as adjunctive therapy experienced more than 40% fewer drop attacks than patients who received placebo (increase of 1.
announced today that the Ministry of Health and Social Development of the Russian Federation has approved the antiepileptic agent
Zonegran(R) (zonisamide) as an adjunctive therapy in the treatment of adult epilepsy patients with partial seizures.
Having commenced fully-fledged operations earlier this year, the company has already launched the antiepileptic agent
Banzel as well as the chemotherapeutic implant Gliadel Wafer for the treatment of certain malignant brain tumors.
Having commenced fully-fledged operations earlier this year, Eisai Canada has already launched the antiepileptic agent
Banzel as well as the chemotherapeutic implant Gliadel Wafer for the treatment of certain malignant brain tumors, and has filed a New Drug Submission (NDS) with the Canadian regulatory authorities for the anticancer agent Halaven, one of Eisai's major global products.
Eisai is actively engaged in product creation activities in China, currently developing such products as Halaven(R) (microtubule dynamics inhibitor), an anticancer agent discovered and developed in-house, and the antiepileptic agent
perampanel (AMPA receptor antagonist) in an effort to expand its portfolio of products in its defined therapeutic areas of focus as it seeks to make contributions to an ever-greater number of patients in China in line with its human health care (hhc) mission.
This phenomenon will depend crucially on GlaxoSmithKline's success in marketing this antiepileptic agent
to medical oncologists.